KalVista Pharmaceuticals Inc
KALV
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.44B
Close$
$21.88
19% downside
Current Fair Value
19% downsideOvervalued by 19% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.44 Billion |
|---|---|
| Enterprise Value | $1.49 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.23 |
| Beta | -0.29 |
| Outstanding Shares | 50,536,000 |
Return
| Return on Equity | 4539.43% |
|---|---|
| Return on Assets | -36.69% |
| Return on Invested Capital | -45.56% |
Valuation & Multiples
| P/E Ratio | -8.36 |
|---|---|
| PEG | 9.32 |
| Price to Sales | 13.5 |
| Price to Book Ratio | -27.0 |
| Enterprise Value to Revenue | 12.31 |
| Enterprise Value to EBIT | -11.78 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -104.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$38.76 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$48.23 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6415▲ 50.36% |
|---|---|
| Total Calls | 1,618,200▲ 1438.21% |
| Total Puts | 1,038,000▲ 7058.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 137.03%▲ 5.49% |
|---|---|
| Total Invested | $1.39B▲ 28.90% |
| Investors Holding | 191▲ 26.00% |
ESG Score
No data
About KalVista Pharmaceuticals Inc
CEO: Thomas Crockett